Therapeutic | Daratumumab |
Target | CD38 |
Heavy Chain | EVQLLESGGGLVQPGGSLRLSCAVSGFTFNSFAMSWVRQAPGKGLEWVSAISGSGGGTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCAKDKILWFGEPVFDYWGQGTLVTVSS |
Light Chain | EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPTFGQGTKVEIK |
100% seqID Fv Structure | 7dun%3AHL%2F7duo%3AHL%2F7dha%3ACB [Fvs: ] |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
100% seqID Structure | 7dun%3AHL%2F7duo%3AHL%2F7dha%3ACB [Fvs: ] |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G1 |
Highest Clinical Trial (August '23) | Approved |
Estimated Status (August '23) | Active |
Recorded Developmental Technology | Medarex HuMAb Mouse |
INN Year Proposed | 2009 |
INN Year Recommended | 2010 |
Companies Involved | Boston Medical Center%3BBristol-Myers Squibb%3BDana-Farber Cancer Institute%3BFrench Innovative Leukemia Organisation%3BGenentech%3BGenmab%3BJanssen Biotech%3BJanssen Research %26 Development%3BM. D. Anderson Cancer Center%3BSyros Pharmaceuticals |
Conditions Approved | Multiple myeloma |
Conditions Active | Amyloid light-chain amyloidosis%3BAcute myeloid leukaemia%3BChronic lymphocytic leukaemia%3BDiffuse large B cell lymphoma%3BFollicular lymphoma%3BMantle-cell lymphoma%3BMyelodysplastic syndromes%3BPrecursor B-cell lymphoblastic leukaemia-lymphoma%3BPrecursor T-cell lymphoblastic leukaemia-lymphoma%3BProstate cancer%3BT-cell lymphoma%3BWaldenstrom%27s macroglobulinaemia%3BSolid tumours |
Conditions Discontinued | Non-small cell lung cancer |
Notes |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]